Morgan Stanley analyst Craig Hettenbach upgraded Doximity (DOCS) to Equal Weight from Underweight with a price target of $53, up from $33.

Morgan Stanley has upgraded Doximity (DOCS) to equal weight from underweight, citing renewed momentum in its business and conservative Q4 guidance. Read more here.

The round saw participation from Perplexity CTO Denis Yarats, Kleiner Perkins Scout Fund, Y Combinator, Snorkel AI CEO Alex ...

Canaccord Genuity on Wednesday downgraded Doximity (NYSE:DOCS) to hold from buy, noting that its shares, after a more than 30% rally following the company’s Q2 results, already reflect high ...

Doximity (DOCS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 7. Analyst Vikram ...

Doximity, Inc. (NASDAQ:DOCS – Get Free Report) shares reached a new 52-week high on Friday . The company traded as high as $57.10 and last traded at $57.10, with a volume of 272953 shares trading ...

Shares of Doximity (NYSE: DOCS) rocketed 35% higher as of 1:45 p.m. ET Friday, according to data provided by S&P Global ...

Record-breaking Q2 earnings, soaring revenue, and bullish analyst upgrades make Doximity the healthcare stock to watch ...

The online medical platform reported quarterly revenue of $136.8 million and earnings of 30 cents a share, beating analysts ...

Doximity's fiscal 2025 Q2 earnings beat analyst and management expectations despite ongoing macroeconomic uncertainties in ...

Pavlo Gonchar / SOPA Images / LightRocket / Getty Images Doximity shares surged Friday morning after the company's second quarter results and outlook for the rest of its fiscal year beat estimates.

The consensus rating for Doximity is Neutral, based on 13 analyst ratings. With an average one-year price target of $37.69, there's a potential 10.13% downside.